Blanchard L, Mijacika A, & Osorio JC*. (2025). Targeting Myeloid Cells for Cancer Immunotherapy. Cancer Immunol Res, 13(11), 1700-1715. https://doi.org/10.1158/2326-6066.CIR-25-0159
Osorio JC*, Knorr DA, Weitzenfeld P, Blanchard L, Yao N, Baez M, Sevilla C, DiLillo M, Rahman J, Sharma VP, Bromberg J, Postow MA, Ariyan C, Robson ME, & Ravetch JV. (2025). Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer. Cancer Cell, 43(10), 1902-1916 e1909. https://doi.org/10.1016/j.ccell.2025.07.013
Osorio JC*, Smith P, Knorr DA, & Ravetch JV. (2023). The antitumor activities of anti-CD47 antibodies require Fc-FcgammaR interactions. Cancer Cell, 41(12), 2051-2065 e2056. https://doi.org/10.1016/j.ccell.2023.10.007
Gomez-Banoy N, Ortiz EJ, Jiang CS, Dagher C, Sevilla C, Girshman J, Pagano AM, Plodkowski AJ, Zammarrelli WA, Mueller JJ, Aghajanian C, Weigelt B, Makker V, Cohen P, & Osorio JC* (2024). Body mass index and adiposity influence responses to immune checkpoint inhibition in endometrial cancer. J Clin Invest, 134(17). https://doi.org/10.1172/JCI180516 *Corresponding author